Iovance Biotherapeutics, Inc. - Common Stock (NQ:IOVA)

14.21 -0.01 (-0.04%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Iovance Biotherapeutics, Inc. - Common Stock

< Previous 1 2

...

18 19 20 21 22 23 24 25 Next >

Why Is Iovance Therapeutics (IOVA) Stock Down 45% Today? ↗

May 27, 2022

Iovance Therapeutics (IOVA) stock is falling hard on Friday following the release of clinical trial data for its melanoma treatment.

Via InvestorPlace

Mid-Morning Market Update: Markets Open Higher; US Goods Trade Deficit Narrows In April ↗

May 27, 2022

U.S. stocks traded higher this morning, with the Dow Jones gaining more than 100 points on Friday.

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

May 27, 2022

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗

May 27, 2022

We're starting the final day of trading for the week with a breakdown of the biggest pre-market stock movers for Friday!

Via InvestorPlace

4 Analysts Have This to Say About Iovance Biotherapeutics ↗

May 24, 2022

Within the last quarter, Iovance Biotherapeutics (NASDAQ:IOVA) has observed the following analyst ratings:

Via Benzinga

Iovance Receives FDA Allowance For IOV-4001 Study In Two Advanced Cancers ↗

March 16, 2022

Via Benzinga

20 Stocks Moving in Friday's Pre-Market Session ↗

May 27, 2022

Gainers Adicet Bio, Inc. (NASDAQ: ACET) rose 16% to $11.90 in pre-market trading after reporting positive clinical update from ADI-001 Phase 1 Trial in relapsed/refractory Non-Hodgkin’s Lymphoma.

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

May 26, 2022

Gainers

Via Benzinga

Iovance Biotherapeutics Just Flashed A Bullish Sign Despite Melanoma Drug Delay ↗

April 07, 2022

This biotech stock is mounting a two-day recovery and is well above its 50-day line.

Via Investor's Business Daily

The Daily Biotech Pulse: BioXcel's Igalmi Gets FDA Nod, Citius Spikes On Positive Phase 3 Data, Iovance Receives Positive Regulatory Feedback For Skin Cancer Therapy ↗

April 06, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

Iovance Outlines Frontline Melanoma Strategy For Lifileucel / Pembrolizumab Combo Therapy ↗

April 06, 2022

The

Via Benzinga

All The Stocks That Moved Wednesday From CNBC's 'Fast Money: Halftime Report' ↗

March 23, 2022

CNBC's "Fast Money: Halftime Report" delivers market-moving news to investors. The commentary delivered by hosts of the show often move the stocks mentioned....

Via Benzinga

The Daily Biotech Pulse: Pfizer-BioNTech Apply For Authorization Of 3rd Booster Shot, Sanofi-Seagen Strike Cancer Therapy Pact, Iovance Gets Nod For Cancer Study ↗

March 16, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

March 15, 2022

Gainers

Via Benzinga

Recap: Iovance Biotherapeutics Q4 Earnings ↗

February 24, 2022

Iovance Biotherapeutics (NASDAQ:IOVA) reported its Q4 earnings results on Thursday, February 24, 2022 at 04:00 PM. Here's what investors need to know about the announcement....

Via Benzinga

The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company ↗

February 24, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (...

Via Benzinga

Iovance's Lifileucel Combo Shows Encouraging Response Rates In Advanced Cancers ↗

November 15, 2021

Iovance Biotherapeutics Inc (NASDAQ: IOVA) has announced data for lifileucel in combination with Merck Co Inc's (NYSE: MRK) Keytruda (pembrolizumab)...

Via Benzinga

The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow ↗

February 20, 2022

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front...

Via Benzinga

Iovance Shares Tumble After Cell Therapy Data From Lung Cancer Trial ↗

November 12, 2021

Iovance Biotherapeutics Inc (NASDAQ: IOVA) has announced additional data for LN-145 in patients with metastatic non-small cell lung cancer (mNSCLC) enrolled in...

Via Benzinga

70 Biggest Movers From Friday ↗

November 15, 2021

Gainers Everspin Technologies, Inc. (NASDAQ: MRAM) shares surged 63.2% to close at $10.74 on Friday after the company reported better-than-expected Q3 results and issued Q4...

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

November 12, 2021

Gainers SOC Telemed (NASDAQ:TLMD) stock increased by 30.04% to $2.77 during Friday's regular session. The current volume of 1.9 million shares is 238.17% of SOC...

Via Benzinga

48 Stocks Moving In Friday's Mid-Day Session ↗

November 12, 2021

Gainers Everspin Technologies, Inc. (NASDAQ: MRAM) shares climbed 41% to $9.28 after the company reported better-than-expected Q3results and issued Q4 sales guidance above...

Via Benzinga

Iovance Biotherapeutics, inc (IOVA) Q3 2021 Earnings Call Transcript ↗

November 05, 2021

IOVA earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

12 Health Care Stocks Moving In Friday's After-Market Session ↗

September 17, 2021

Gainers Corvus Pharmaceuticals (NASDAQ:CRVS

Via Benzinga

The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO ↗

November 04, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &...

Via Benzinga

Why Iovance Is Up Nearly 11% Today ↗

September 15, 2021

Investors are starting to connect some drug development dots... with a little help.

Via The Motley Fool

The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline ↗

October 31, 2021

Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...

Via Benzinga

Cathie Wood's Ark ETFs Underperformed The Broader Market In Q2, With Workhorse, Virgin Galactic, Coinbase, Teladoc Taking Big Toll ↗

July 15, 2021

ARK Invest, the New York-based investment management firm led by the popular money manager Cathie Wood, saw its five actively managed exchange-traded funds and two self-indexed...

Via Benzinga

Why Iovance Biotherapeutics Soared 40% In June ↗

July 08, 2021

The biopharma outfit has put some red flags in the rearview mirror, and sees a plausible approval on the horizon.

Via The Motley Fool

June’s Best and Worst Performing Russell 1,000 Stocks ↗

June 29, 2021

The month of June, the second quarter and the first half of 2021 are almost in the bag.

Via Talk Markets

< Previous 1 2

...

18 19 20 21 22 23 24 25 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.